21 recruiting, 9 active not recruiting, 9 completed, 7 unknown. 30 Phase 2, 18 Phase 1, 12 Phase 3, 1 Not applicable.
Follow mFOLFIRINOX: new trials by email Literature Review of mFOLFIRINOX trials Research Report on mFOLFIRINOX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation RO7836748, Pembrolizumab, mFOLFIRINOX - Solid Tumors | Phase 1 | Not yet recruiting | Hoffmann-La Roche | 540 | 2026-12-31 | 2026-10-30 |
| A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma GDC-7035, Panitumumab, mFOLFOX6 - Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | Genentech, Inc. | 388 | 2026-10-31 | 2026-10-13 |
| A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer ELI-002 7P, Tislelizumab, mFOLFIRINOX - Pancreatic Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2026-06-22 | 2026-10-28 |
| Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma. Nab paclitaxel / gemcitabine, mFOLFIRINOX - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Federation Francophone de Cancerologie Digestive | 110 | 2026-06-01 | 2026-06-11 |
| A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer BMS-986504, Gemcitabine, Nab-paclitaxel - Phase 2 Study, BMS-986504 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 60 | 2026-04-09 | 2026-10-05 |
| A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma INCB161734, Placebo, Investigator's choice of chemotherapy - Solid Tumors | Phase 3 | Recruiting | Incyte Corporation | 588 | 2026-04-09 | 2026-10-30 |
| Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer Surufatinib, Toripalimab, mFOLFIRINOX - Pancreatic Cancer Resectable | Phase 2 | Not yet recruiting | Sun Yat-sen University | 30 | 2026-03-31 | 2026-03-13 |
| A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer Pumitamig, Nab-paclitaxel, Gemcitabine - Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Recruiting | BioNTech SE | 105 | 2025-12-04 | 2026-07-28 |
| M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors M0324, Pembrolizumab, mFOLFIRINOX - Advanced Solid Tumor | Phase 1 | Recruiting | EMD Serono Research & Development Institute, Inc. | 77 | 2025-10-10 | 2026-11-02 |
| A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer zolbetuximab, mFOLFIRINOX - Metastatic Pancreatic Adenocarcinoma | Phase 1 | Active not recruiting | Astellas Pharma Global Development, Inc. | 12 | 2025-09-24 | 2026-10-16 |
| MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma Zunsemetinib, mFOLFIRINOX - Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | Phase 1 | Recruiting | Washington University School of Medicine | 51 | 2025-06-13 | 2026-04-30 |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients TNG462, RMC-9805, RMC-6236 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 183 | 2025-05-31 | 2026-10-23 |
| BBO-11818 in Adult Subjects With KRAS Mutant Cancer BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin) - Non-Small Cell Lung Cancer, NSCLC | Phase 1 | Recruiting | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 665 | 2025-03-31 | 2026-06-02 |
| A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation INCB186748, Cetuximab, GEMNabP - Solid Tumors | Phase 1 | Active not recruiting | Incyte Corporation | 30 | 2025-03-27 | 2026-08-25 |
| A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations ALTA3263, cetuximab, mFOLFOX6 - Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Alterome Therapeutics, Inc. | 448 | 2025-03-05 | 2026-10-26 |
| Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients mFOLFIRINOX, mFolfox6 - Rectum Cancer | Phase 2 | Recruiting | Menoufia University | 100 | 2025-01-25 | 2025-02-19 |
| Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer Bortezomib Injection, Sintilimab, mFOLFIRINOX - Pancreas Cancer | Phase 1 / Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 63 | 2024-11-15 | 2025-01-10 |
| Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat - Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Gulam Manji | 60 | 2024-05-10 | 2026-02-27 |
| A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer OT-101, mFOLFIRINOX - Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Oncotelic Inc. | 455 | 2024-05-01 | 2024-08-13 |
| Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma BNT321 0.5 mg/kg, BNT321 DL 2, mFOLFIRINOX - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | BioNTech SE | 1 | 2024-03-27 | 2025-10-31 |
Showing 20 of 54. Sign in to see all of them.
Pancreatic Neoplasms (20) · Colorectal Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (4) · Colonic Neoplasms (3) · Neoplasms (3) · Rectal Neoplasms (3) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Adenocarcinoma (1) · Bile Duct Neoplasms (1) · Breast Neoplasms (1) · Carcinoma (1) · Medullary cystic kidney disease 1 (1) · Neoplasms by Site (1)
Incyte Corporation (3) · BioNTech SE (2) · Fudan University (2) · Genentech, Inc. (2) · Memorial Sloan Kettering Cancer Center (2) · UNICANCER (2) · Alliance for Clinical Trials in Oncology (1) · Alterome Therapeutics, Inc. (1) · Asan Medical Center (1) · Associazione Italiana per lo Studio del Pancreas (1) · Astellas Pharma Global Development, Inc. (1) · Australasian Gastro-Intestinal Trials Group (1) · Baylor College of Medicine (1) · Case Comprehensive Cancer Center (1) · Centre Hospitalier Universitaire de Saint Etienne (1)
United States (27) · France (9) · Canada (8) · China (8) · Australia (5) · Japan (4) · South Korea (4) · Belgium (3) · Italy (3) · Spain (3) · Brazil (2) · Germany (2) · Netherlands (2) · Puerto Rico (2) · Sweden (2)
Andrew Oar (1) · Benjamin Weinberg, MD (1) · Changhoon Yoo, MD, PhD (1) · David Bajor, MD (1) · Diogo Gomes, MD (1) · Ernest R. Camp, M.D., M.S.C.R., F.A.C.S. (1) · Gulam Manji, MD, PhD (1) · Jean-Marc Phelip, PhD (1) · Juan Du, MD (1) · Kevin Soares, MD (1)
PMID 28750659, PMID 30575490, PMID 31068222, PMID 33862000, PMID 34662180, PMID 35834226, PMID 36048453, PMID 37034685, PMID 37268519, PMID 37717786, PMID 38492812, PMID 38553680, PMID 39008208, PMID 39232761, PMID 41275879, PMID 41790032, PMID 42098550, PMID 42546248, PMID 42733563
2023 (2), 2014 (1), 2015 (1), P30CA012197 (1), P50CA272213 (1), U10CA180868 (1)